Tandem Diabetes Care (Nasdaq:TNDM) today announced study findings highlighting the benefits of its automated insulin delivery ...

Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the ...

Leerink analyst Mike Kratky notes that a new sub-analysis showing similar clinical benefits of AID in T2 patients regardless of their C-peptide ...

Patients with type 1 and type 2 diabetes present similar symptoms, however, the causes are not the same. Type 1 diabetes, which is characterized by deficient insulin production, is considered to be ...

What is the role of C peptide in managing uncontrolled type 2 diabetes? —Ndukwe H. Odeluga, MD, Bakersfield, Calif. Cleaved from proinsulin to make mature insulin, C peptide can be considered a marker ...

Care announced the publication of a study in the American Diabetes Association’s Diabetes Care journal. The study, a ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

Dear Dr. Roach: I was recently diagnosed with Type 1 diabetes at the age of 62. My mother was diagnosed with Type 1 diabetes at 57. My glutamic acid decarboxylase 65 (GAD65) antibody results came in ...

Most patients with new-onset type 1 diabetes have substantial intact beta-cell reserve. 1 Thus, we analyzed the efficacy of semaglutide, an agonist of glucagon-like peptide 1 (GLP-1), in patients with ...

Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...